Market Place
Sourcing Support
Contineum Therapeutics Initiates PET Trial Dosing of PIPE-791
16 Dec 2024 //
BUSINESSWIRE
Contineum to Attend 7th Annual Evercore HealthCONx Conference
25 Nov 2024 //
BUSINESSWIRE
Contineum`s PIPE-791 Development with FDA IND for Chronic Pain
18 Nov 2024 //
BUSINESSWIRE
Contineum Therapeutics to Attend Upcoming Investor Conferences
13 Nov 2024 //
BUSINESSWIRE
Contineum Therapeutics Reports Q3 2024 Results & Highlights
06 Nov 2024 //
BUSINESSWIRE
Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences
28 Aug 2024 //
BUSINESSWIRE
Contineum Therapeutics Reports Q2 2024 Results And Business Highlights
13 Aug 2024 //
BUSINESSWIRE
Contineum Publishes PIPE-307 Data For Multiple Sclerosis
31 Jul 2024 //
BUSINESSWIRE
Contineum announces Sarah Boyce`s appointment to the board of directors.
24 Jun 2024 //
BUSINESSWIRE
Contineum: Presenting At Goldman Sachs Healthcare Conference
04 Jun 2024 //
BUSINESSWIRE
Contineum Appoints John Healy As General Counsel, Corporate Secretary
03 Jun 2024 //
BUSINESSWIRE
Contineum Appoints Troy Ignelzi To Board Of Directors
20 May 2024 //
BUSINESSWIRE
Contineum Reports Q1 2024 Financials, Business Highlights
16 May 2024 //
BUSINESSWIRE
Contineum Therapeutics Announces Pricing of Initial Public Offering
04 Apr 2024 //
GLOBENEWSWIRE
New year, new name for Pipeline, Novozymes and Chr. Hansen
15 Dec 2023 //
FIERCE PHARMA
Pipeline Therapeutics Changes Name to Contineum Therapeutics
13 Dec 2023 //
BUSINESSWIRE
Pipeline Therapeutics to Participate in Upcoming Investor Conferences
04 Oct 2023 //
BUSINESSWIRE
Pipeline Therapeutics to Participate in Multiple Upcoming Investor Conferences
07 Sep 2023 //
BUSINESSWIRE
Pipeline Therapeutics Announces First Subject Dosed with PIPE-791 in Ph 1 Study
01 Aug 2023 //
BUSINESSWIRE
Pipeline Receives IND Clearance from FDA to Initiate Phase 1 Study of PIPE-791
08 Jun 2023 //
BUSINESSWIRE
Pipeline to Present at 2023 Global Healthcare Conference
25 May 2023 //
BUSINESSWIRE
Pipeline Therapeutics to Present at the 2023 RBC Global Healthcare Conference
04 May 2023 //
BUSINESSWIRE
Pipeline Announces Participation at the 2023 Stifel CNS Days Conference
21 Mar 2023 //
BUSINESSWIRE
Pipeline to Present Preclinical Poster on PIPE-791 at the Glial Biology
06 Mar 2023 //
BUSINESSWIRE
Pipeline Announces Participation in RBC Capital Markets Healthcare Conference
01 Dec 2022 //
BUSINESSWIRE
Pipeline Therapeutics to Present Multiple Posters at SFN 2022
08 Nov 2022 //
BUSINESSWIRE
Pipeline Announces Participation in Upcoming Investor Conferences in Nov
01 Nov 2022 //
BUSINESSWIRE
Pipeline Therapeutics Announces Participation in Upcoming Investor Conferences
04 Oct 2022 //
BUSINESSWIRE
Pipeline to Participate in the UBS Virtual Biotech Private Company Symposium
08 Sep 2022 //
BUSINESSWIRE
Pipeline Therapeutics to Present at the 2022 Jefferies Global Conference
26 May 2022 //
BUSINESSWIRE
Pipeline Therapeutics to Present at Multiple Investor Conferences in May 2022
11 May 2022 //
BUSINESSWIRE
Pipeline Therapeutics to Present at Needham Healthcare Conference
05 Apr 2022 //
BUSINESSWIRE
FDA Clears Pipeline` IND to Initiate Phase 1b/2a Study of PIPE-307
28 Mar 2022 //
BUSINESSWIRE
Pipeline Therapeutics to Present at Upcoming March Investor Conferences
14 Mar 2022 //
BUSINESSWIRE
Pipeline Tx Reports Positive Phase 1 Clinical Results for PIPE-307 in MS
10 Mar 2022 //
BUSINESSWIRE
Pipeline Therapeutics Appoints Scott Oross as General Counsel
26 Jun 2021 //
BUSINESSWIRE
Pipeline Therapeutics Initiates Phase 1 Clinical Trial of PIPE-307
02 Mar 2021 //
BUSINESSWIRE
Pipeline Therapeutics Completes $80 Million Series C Financing
11 Feb 2021 //
BUSINESSWIRE
Pipeline Therapeutics to Present at BMO’s Fall Private Company Showcase 2020
08 Oct 2020 //
BUSINESSWIRE
Pipeline Therapeutics Initiates Phase 1/2a Clinical Trial of PIPE-505
23 Jul 2020 //
BUSINESSWIRE
Pipeline Initiates Ph 1/2a Trial PIPE-505 in Sensorineural Hearing Loss
22 Jul 2020 //
BUSINESSWIRE
Pipeline Therapeutics to Present at the Jefferies Virtual Global Conference
28 May 2020 //
BUSINESSWIRE
Pipeline Therapeutics Completes $30 Million Series B Financing
18 Dec 2019 //
BUSINESS WIRE
